Depression in Hemorrhagic Stroke

Patients who suffered aneurysmal subarachnoid hemorrhage will be randomly assigned either an
oral antidepressant or placebo and evaluated for the preventative treatment of depression and
health-related quality-of-life.

Inclusion Criteria:

Patients 18-85 years of age aged 18 years and older will be included.

Patients admitted for subarachnoid hemorrhage from a ruptured cerebral aneurysm will be
included.

Only patients who provide informed consent will be included.

Exclusion Criteria:

Non-English speaking patients will be excluded.

Patients currently receiving therapy for depression or related mental health diagnoses
before admission will be excluded.

Patients with medical contraindications to fluoxetine therapy will be excluded.

Pregnant patients or patients considering pregnancy during the trial period at the time of
consent will be excluded.

Patients with active psychosis will be excluded.

Patients who are incarcerated or in police custody will be excluded.

Patients with a comorbidity or cognitive impairment (as determined by a
recruiter-administered Montreal Cognitive Assessment; Patients scoring >26 are considered
of appropriate cognitive function for consent) that precludes informed consent and
participation in the research interviews will be excluded.